David D. O'Toole - 18 Feb 2026 Form 4 Insider Report for AVITA Medical, Inc. (RCEL)

Reporting relationship: CFO
Issuer ticker: RCEL
Reported as of: 18 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 Feb 2026, 16:38:20 UTC
Prior SEC filing: 26 Aug 2025
Next SEC filing: 23 Feb 2026
Source filing: View source filing
Reporting owner signature: David O'Toole

Key filing fact

David D. O'Toole filed Form 4 for AVITA Medical, Inc. (RCEL) on 19 Feb 2026.

Key facts

This page summarizes David D. O'Toole's Form 4 filing for AVITA Medical, Inc. (RCEL).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 19 Feb 2026, 16:38.

Change

Previous filing in this sequence was filed on 26 Aug 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001491140 Primary reporting owner

O'Toole David D

Relationship: CFO
Address: 28159 AVENUE STANFORD, SUITE 220 - AVITA MEDICAL, VALENCIA
Signature: David O'Toole
Signature date: 19 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RCEL transaction

Common Stock

Award

Transaction value
Shares: +105,470
Change %: +333%
Price
Shares after: 137,127
Date: 18 Feb 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RCEL transaction Derivative

Stock Options (Right to Buy)

Award

Transaction value: $0
Shares: +155,510
Change %
Price: $0.000000
Shares after: 155,510
Date: 18 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 155,510
Exercise price: $4.31
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents an award of restricted stock units (the "RSUs"), each RSU representing a contingent right to be issued one share of Common Stock of the Company (the "Common Stock"), that are subject to time-based vesting criteria. These RSUs vest in three equal annual installments beginning on the date 12 months following the grant date of February 18, 2026.

Footnote F2

Includes unvested RSUs.

Footnote F3

These Stock Options vest in three equal annual installments beginning the first anniversary of the grant date of February 18, 2026.